Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM350 in Patients With Advanced Solid Tumors
NCT05263960Phase 2Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cm350 in solid tumor (advanced stage) and hepatocellular carcinoma (HCC) (3 arms), sponsored by Keymed Biosciences. Primary endpoints: Incidence of Adverse events (AEs) up to 5 years, Dose-Limiting Toxicity and 3 more. Started Apr 2022; status: recruiting.
02
Drugs
cm350
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05263960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263960.